Clinical Trial

Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination with Pembrolizumab, in Unresectable Melanoma Patients

Study acronym: INTACT/MeRCI
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The trial aims to evaluate the efficacy of single agent L19IL2, single agent L19TNF, and combination L19IL2+L19TNF given concurrently with anti-PD1 therapy compared to historical control of anti-PD-1 re-challenge alone for anti-PD1 refractory unresectable stage III-IV melanoma.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-02-21; most recent amendment 2024-10-23.
Status change: Active, Not Recruiting → Recruiting 2024-10-23
Trial Details
NCT Number NCT06284590
Lead Sponsor Philogen S.p.A.
Collaborators: Merck Sharp & Dohme LLC
Conditions Melanoma Stage III, Melanoma Stage IV
Enrollment 162 participants
Start Date 2024-07-12
Primary Completion 2028-07 (estimated)
Study Completion 2028-07 (estimated)
Updated on ClinicalTrials.gov 2024-10-26